Natalizumab is a new treatment option for patients with active relapsing-remitting multiple
sclerosis. In phase III studies, natalizumab was highly effective and well tolerated; however …

Background Natalizumab (NTZ)(Tysabri®) is a monoclonal antibody that inhibits leukocyte
migration across the blood‐brain barrier, thus reducing inflammation in central nervous …

Progressive multifocal leukoencephalopathy (PML) is a rare and devastating neurological
disease with areas of demyelination in the central nervous system classically associated …

The implementation of a variety of immunosuppressive therapies has made drug-associated
progressive multifocal leukoencephalopathy (PML) an increasingly prevalent clinical entity …

Objective To determine risk factors for progressive multifocal leukoencephalopathy (PML) in
systemic lupus erythematosus (SLE) patients, and understand how underlying disease or …

Progressive multifocal leukoencephalopathy (PML) is a disease of the central nervous
system caused by neuropathogenic prototypes of ubiquitous community-acquired JC virus …

224 Letters to the Editor ß The Author 2007. Published by Oxford University Press on behalf
of the British Society for Rheumatology. All rights reserved. For Permissions, please email …

SIR, PV, a 38-yr-old patient with a 13-yr history of SLE, was admitted to our hospital because
of occipital headache, blurring of vision and seizures after treatment with the second weekly …

The functional -169T-->C single-nucleotide polymorphism in FCRL3 is not associated with
rheumatoid arthritis in white North Americans The functional -169T-->C single-nucleotide …

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central
nervous system (CNS) caused by the human neurotropic polyomavirus JC (JCV). The …